MX367663B - Composición farmacéutica para el tratamiento de la eyaculación precoz y método para el tratamiento de la eyaculación precoz. - Google Patents

Composición farmacéutica para el tratamiento de la eyaculación precoz y método para el tratamiento de la eyaculación precoz.

Info

Publication number
MX367663B
MX367663B MX2014000082A MX2014000082A MX367663B MX 367663 B MX367663 B MX 367663B MX 2014000082 A MX2014000082 A MX 2014000082A MX 2014000082 A MX2014000082 A MX 2014000082A MX 367663 B MX367663 B MX 367663B
Authority
MX
Mexico
Prior art keywords
premature ejaculation
pharmaceutical composition
treating premature
present
composition
Prior art date
Application number
MX2014000082A
Other languages
English (en)
Other versions
MX2014000082A (es
Inventor
Hyun-Jung Park
Sun-Ahe Lee
Hong-Ryeol Jeon
Bong-Sang Lee
Do-Woo Kwon
Seong-Shin Kwak
Jeong-Hwa Yoo
Original Assignee
Ctc Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctc Bio Inc filed Critical Ctc Bio Inc
Publication of MX2014000082A publication Critical patent/MX2014000082A/es
Publication of MX367663B publication Critical patent/MX367663B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica para el tratamiento, prevención o alivio de los síntomas de la eyaculación precoz, que se administra a petición del paciente antes de la actividad sexual, comprendiendo la composición clorhidrato de clomipramina como ingrediente activo en una cantidad de 14 a 16 mg, de preferencia alrededor de 15 mg. Con mayor preferencia, la composición de la presente invención comprende además almidón pregelatinizado y almidón glicolato sódico. La composición farmacéutica de la presente invención puede proporcionar efectos de aparición rápida, reducir la variación de la disolución (captación) de acuerdo con las condiciones del pH gastrointestinal del paciente y minimizar los efectos secundarios.
MX2014000082A 2011-06-28 2012-06-28 Composición farmacéutica para el tratamiento de la eyaculación precoz y método para el tratamiento de la eyaculación precoz. MX367663B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110062620 2011-06-28
PCT/KR2012/005134 WO2013002578A2 (ko) 2011-06-28 2012-06-28 조루증 치료용 약학 조성물 및 조루증 치료 방법

Publications (2)

Publication Number Publication Date
MX2014000082A MX2014000082A (es) 2014-05-01
MX367663B true MX367663B (es) 2019-08-30

Family

ID=47424682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000082A MX367663B (es) 2011-06-28 2012-06-28 Composición farmacéutica para el tratamiento de la eyaculación precoz y método para el tratamiento de la eyaculación precoz.

Country Status (19)

Country Link
US (2) US20140200210A1 (es)
EP (2) EP2727595B1 (es)
JP (1) JP6042886B2 (es)
KR (1) KR101978459B1 (es)
CN (1) CN103635194B (es)
AU (1) AU2012276476B2 (es)
BR (1) BR112013033475A2 (es)
CA (1) CA2840521C (es)
EA (1) EA029932B1 (es)
ES (1) ES2668943T3 (es)
IL (1) IL230174A (es)
MA (1) MA35610B1 (es)
MX (1) MX367663B (es)
MY (1) MY167609A (es)
SG (1) SG10201605314TA (es)
TN (1) TN2013000526A1 (es)
UA (1) UA112652C2 (es)
WO (1) WO2013002578A2 (es)
ZA (1) ZA201400653B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394413B (es) * 2013-12-31 2025-03-24 Ctc Bio Inc Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
NZ545484A (en) * 2003-09-15 2009-09-25 Vectura Ltd Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
CA2613617A1 (en) * 2005-06-27 2007-01-04 Daniel Drai Compositions and methods for enhancement of sexual function
US20070166344A1 (en) 2006-01-18 2007-07-19 Xin Qu Non-leaching surface-active film compositions for microbial adhesion prevention
TW201008486A (en) 2008-02-20 2010-03-01 Daiwa Spinning Co Ltd Antiviral substance, antiviral fiber, and antiviral fiber structure
BRPI0912890A2 (pt) * 2008-05-19 2015-10-20 Hyun Uk Seol composição farmacêutica para o tratamento de ejaculação precoce
KR20110062620A (ko) 2009-12-03 2011-06-10 유비벨록스(주) 전자지갑디바이스를 이용한 금융 제휴서비스 제공시스템 및 이를 이용한 금융 제휴서비스제공방법

Also Published As

Publication number Publication date
MX2014000082A (es) 2014-05-01
EP2727595B1 (en) 2018-02-21
EP3323416A1 (en) 2018-05-23
MA35610B1 (fr) 2014-11-01
EP2727595A2 (en) 2014-05-07
ES2668943T3 (es) 2018-05-23
ZA201400653B (en) 2016-11-30
JP6042886B2 (ja) 2016-12-14
US20190224208A1 (en) 2019-07-25
AU2012276476A1 (en) 2014-02-13
EP3323416B1 (en) 2020-04-22
KR20140043898A (ko) 2014-04-11
US20140200210A1 (en) 2014-07-17
AU2012276476B2 (en) 2017-06-29
MY167609A (en) 2018-09-20
WO2013002578A2 (ko) 2013-01-03
CN103635194B (zh) 2016-02-10
CA2840521C (en) 2019-11-26
HK1193050A1 (zh) 2014-09-12
EP2727595A4 (en) 2015-03-04
JP2014527513A (ja) 2014-10-16
BR112013033475A2 (pt) 2017-12-19
IL230174A (en) 2017-07-31
SG10201605314TA (en) 2016-08-30
EA201490173A1 (ru) 2014-04-30
WO2013002578A3 (ko) 2013-04-11
CN103635194A (zh) 2014-03-12
CA2840521A1 (en) 2013-01-03
UA112652C2 (uk) 2016-10-10
TN2013000526A1 (en) 2015-03-30
KR101978459B1 (ko) 2019-05-14
EA029932B1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
BR112014004435A2 (pt) inibidores de quinase rock
UA108887C2 (xx) Кристалічна форма бензил-бензольного інгібітора sglt2
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201270617A2 (ru) Способы лечения или предотвращения тромбоза стента
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2015007488A (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib.
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
TN2013000526A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
EP2464355A4 (en) SUBSTITUTED TRIAZOLPHTHALAZINE DERIVATIVES
UA111145C2 (uk) Фармацевтична композиція
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
UA92208C2 (ru) Способ лечения диабетической ангионевроретинопатии

Legal Events

Date Code Title Description
FG Grant or registration